One of the major reason for unsuccessful outcomes are the adverse events (AEs) from TB medications, which can disrupt treatment and reduce success rates. Dr. Simon Tiberi shared practical advice for healthcare teams to prevent treatment interruptions.

Learn more: https://bit.ly/4qqxfgu

Collaboration in AMR R&D is multisectoral, but not every question moves a project forward. Early scientific advice from EMA is key to understanding what to ask (and not to).
🎥 Watch the complete webinar at: https://bit.ly/4mpXPTx

In AMR research, success rarely comes easy. From LpxH inhibitors under Uppsala University to PhagoMed’s pivot (now BioNTech) and Disperazol’s 15-year journey, each story shows how barriers can be turned into pathways for progress.
👉 Hear their lessons and takeaways here: https://bit.ly/47n6d2v

TB care starts in communities, where CSOs help guide and support care, adherence & recovery. True progress needs equal partnerships, yet the sustained funding lags.

Join UNITE4TB & ERS panel on meaningful TB community engagement: bit.ly/412Cyrf